The Oncosearch | Oncotarget

The immune-related microRNA miR-146b is upregulated in glioblastoma recurrence Research Paper

Shariq S. Khwaja, Chunyu Cai, Shahed N. Badiyan, Xiaowei Wang, Jiayi Huang

Published Jun 26, 2018 · Vol. 9, No. 49 · pp. 29036-29046

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells Research Paper

Eva Hajek, Franziska Krebs, Rebekka Bent, Katharina Haas, Antje Bast, Ivo Steinmetz, Andrea Tuettenberg, Stephan Grabbe, Matthias Bros

Published Jun 19, 2018 · Vol. 9, No. 47 · pp. 28294-28308

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians Clinical Research Papers

Katharina C. KÃ¤hler, Christine Blome, Andrea Forschner, Ralf Gutzmer, Axel Hauschild, Lucie Heinzerling, Elisabeth Livingstone, Carmen Loquai, Tina MÃ¼ller-Brenne, Dirk Schadendorf, Jochen Utikal, Tobias Wagner, Matthias Augustin

Published May 25, 2018 · Vol. 9, No. 40 · pp. 26217-26225

Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma Research Paper

Michelle L. Chadwick, Adam Lane, Dana Thomas, Amanda R. Smith, Angela R. White, Dominique Davidson, Yuxin Feng, Elisa Boscolo, Yi Zheng, Denise M. Adams, Anita Gupta, AndrÃ© Veillette, Lionel M.L. Chow

Published May 15, 2018 · Vol. 9, No. 37 · pp. 24750-24765

Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors Research Paper

Elliot John Kahen, Andrew Brohl, Diana Yu, Darcy Welch, Christopher L. Cubitt, Jae K. Lee, Yunyun Chen, Sean J. Yoder, Jamie K. Teer, Yonghong O. Zhang, Margaret R. Wallace, Damon R. Reed

Published Apr 27, 2018 · Vol. 9, No. 32 · pp. 22571-22585

Selumetinib-based therapy in uveal melanoma patient-derived xenografts Research Paper

Didier Decaudin, Rania El Botty, BÃ©rÃ© Diallo, Gerald Massonnet, Justine Fleury, Adnan Naguez, ChloÃ© Raymondie, Emma Davies, Aaron Smith, Joanne Wilson, Colin Howes, Paul D. Smit, Nathalie Cassoux, Sophie Piperno-Neumann, Sergio Roman-Roman, Fariba NÃ©mati

Published Apr 24, 2018 · Vol. 9, No. 31 · pp. 21674-21686

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients Research Paper

Maria Rosaria Ricciardi, Valentina Salvestrini, Roberto Licchetta, Simone Mirabilii, Mattia Forcato, Gabriele Gugliotta, Simona Salati, Fausto Castagnetti, Gianantonio Rosti, Massimo Breccia, Giuliana Alimena, Rossella Manfredini, Silvio Bicciato, Roberto Massimo Lemoli, Agostino Tafuri

Published Apr 24, 2018 · Vol. 9, No. 31 · pp. 21758-21769

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells Research Paper

Mahiro Iizuka-Ohashi, Motoki Watanabe, Mamiko Sukeno, Mie Morita, Ngoc Thi Hong Hoang, Takahiro Kuchimaru, Shinae Kizaka-Kondoh, Yoshihiro Sowa, Koichi Sakaguchi, Tetsuya Taguchi, Toshiyuki Sakai

Published Apr 13, 2018 · Vol. 9, No. 28 · pp. 19597-19612

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma Research Paper

Valentina Audrito, Antonella ManagÃ², Federica Zamporlini, Eliana Rulli, Federica Gaudino, Gabriele Madonna, Stefania D'Atri, Gian Carlo Antonini Cappellini, Paolo Antonio Ascierto, Daniela Massi, Nadia Raffaelli, Mario MandalÃ, Silvia Deaglio

Published Apr 10, 2018 · Vol. 9, No. 27 · pp. 18997-19005

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas Research Paper

Stefania Acciardo, Lionel Mignion, Nicolas Joudiou, Caroline Bouzin, Jean-FranÃ§ois Baurain, Bernard Gallez, BÃ©nÃ©dicte F. Jordan

Published Mar 30, 2018 · Vol. 9, No. 24 · pp. 16832-16846

Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells Research Paper

Miao Wang, Alex Yuang-chi Chang

Published Mar 27, 2018 · Vol. 9, No. 23 · pp. 16533-16546

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer Research Paper

Amir Noeparast, Philippe Giron, Sylvia De Brakeleer, Carolien Eggermont, Ulrike De Ridder, Erik Teugels, Jacques De GrÃ¨ve

Published Mar 23, 2018 · Vol. 9, No. 22 · pp. 16110-16123

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [¹⁸F] fluorodeoxyglucose (¹⁸F-FDG PET) Research Paper

Geraldine H. Chang, Razelle Kurzrock, Lisa Tran, Maria Schwaederle, Carl K. Hoh

Published Mar 6, 2018 · Vol. 9, No. 18 · pp. 14306-14310

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models Research Paper

Francesca Vena, Ruochen Jia, Arman Esfandiari, Juan J. Garcia-Gomez, Manuel Rodriguez-Justo, Jianguo Ma, Sakeena Syed, Lindsey Crowley, Brian Elenbaas, Samantha Goodstal, John A. Hartley, Daniel Hochhauser

Published Jan 22, 2018 · Vol. 9, No. 14 · pp. 11592-11603

Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia Priority Research Paper

Shuhua Zheng, Gilles M. Leclerc, Bin Li, Ronan T. Swords, Julio C. Barredo

Published Dec 31, 2017 · Vol. 9, No. 5 · pp. 5529-5544

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer Research Paper

Niranjan Awasthi, Sheena Monahan, Alexis Stefaniak, Margaret A. Schwarz, Roderich E. Schwarz

Published Dec 25, 2017 · Vol. 9, No. 4 · pp. 5274-5286

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF^V600E-mutant melanoma Research Paper

Antoneicka L. Harris, Samantha E. Lee, Louis K. Dawson, Laura A. Marlow, Brandy H. Edenfield, William F. Durham, Thomas J. Flotte, Michael Thompson, Daniel L. Small, Aidan J. Synnott, Svetomir N. Markovic, John A. Copland

Published Dec 23, 2017 · Vol. 9, No. 13 · pp. 10905-10919

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

The immune-related microRNA miR-146b is upregulated in glioblastoma recurrence Research Paper

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells Research Paper

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians Clinical Research Papers

Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma Research Paper

Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors Research Paper

Selumetinib-based therapy in uveal melanoma patient-derived xenografts Research Paper

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients Research Paper

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells Research Paper

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma Research Paper

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas Research Paper

Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells Research Paper

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer Research Paper

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [¹⁸F] fluorodeoxyglucose (¹⁸F-FDG PET) Research Paper

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models Research Paper

Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia Priority Research Paper

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer Research Paper

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF^V600E-mutant melanoma Research Paper

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer Research Paper

Role of ginsenosides in reactive oxygen species-mediated anticancer therapy Review

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

The immune-related microRNA miR-146b is upregulated in glioblastoma recurrence Research Paper

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells Research Paper

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians Clinical Research Papers

Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma Research Paper

Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors Research Paper

Selumetinib-based therapy in uveal melanoma patient-derived xenografts Research Paper

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients Research Paper

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells Research Paper

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma Research Paper

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas Research Paper

Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells Research Paper

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer Research Paper

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET) Research Paper

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models Research Paper

Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia Priority Research Paper

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer Research Paper

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma Research Paper

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer Research Paper

Role of ginsenosides in reactive oxygen species-mediated anticancer therapy Review

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth Research Paper

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [¹⁸F] fluorodeoxyglucose (¹⁸F-FDG PET) Research Paper

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF^V600E-mutant melanoma Research Paper